Concordance of c‐kit Mutational Status in Matched Primary and Metastatic Cutaneous Canine Mast Cell Tumors at Baseline. (26th December 2013)

• Record Type: Journal Article
• Authors: Marconato, L.; Zorzan, E.; Giantin, M.; Di Palma, S.; Cancedda, S.; Dacasto, M.
• Is Part Of: Journal of veterinary internal medicine. Volume 28:Number 2(2014:Mar./Apr.)
• Page Start: 547
• Page End: 553
• Publication Date: 2013-12-26
• Subjects: Veterinary medicine -- Periodicals; 636.0896
• DOI: 10.1111/jvim.12266
• Languages: English
• ISSNs: 0891-6640

Abstract

<abstract abstract-type="main" id="jvim12266-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jvim12266-sec-0001" sec-type="section"> <title>Background</title> <p>Mutation analysis of proto‐oncogene <italic>c‐kit</italic> (<italic>c‐kit</italic>) is advisable before starting treatment with tyrosine kinase inhibitors in dogs with mast cell tumor (MCT), including those with metastatic disease. Testing is usually performed on primary tumors, assuming that <italic>c‐kit</italic> mutation status does not change in metastasis.</p> </sec> <sec id="jvim12266-sec-0002" sec-type="section"> <title>Hypothesis/Objectives</title> <p>To give an insight into the mutational processes and to make a recommendation on the use of <italic>c‐kit</italic> mutational analysis in the clinical setting.</p> </sec> <sec id="jvim12266-sec-0003" sec-type="section"> <title>Animals</title> <p>Twenty‐one client‐owned dogs with metastatic MCT.</p> </sec> <sec id="jvim12266-sec-0004" sec-type="section"> <title>Methods</title> <p>Dogs undergoing resection or biopsy for both primary and matched metastatic MCT were prospectively enrolled. Total RNA or DNA was extracted from primary MCT and corresponding metastases. Exons 8, 9, and 11 were amplified by PCR and sequenced. Genetic features between primary MCT and metastases were compared. Their correlation with clinicopathologic features was investigated.</p> </sec> <sec id="jvim12266-sec-0005" sec-type="section"> <title>Results</title> <p>Concordance (mutated or wild‐type) of mutational status, evaluable in 21 primary and matched metastatic (20 nodal and 1 splenic) MCTs, was 100%. Three new <italic>c‐kit</italic> mutations were identified. No significant correlation was detected between <italic>c‐kit</italic> mutation and clinicopathologic features.</p> </sec> <sec id="jvim12266-sec-0006" sec-type="section"> <title>Conclusions and Clinical Importance</title> <p>Proto‐oncogene <italic>c‐kit</italic> mutational status is conserved between any primary and its matched secondary tumor, suggesting that both can be used for <italic>c‐kit</italic> mutational testing. Targeted therapies might be also used to treat metastatic disease.</p> </sec> </abstract>